Canaccord Genuity analyst Caitlin Roberts maintained a Hold rating on Smith & Nephew Snats today and set a price target of $32.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Caitlin Roberts has given his Hold rating due to a combination of factors that balance encouraging momentum with execution risk and valuation restraint. Stronger-than-expected overall growth, driven by Sports Medicine and resilient performance in areas like U.S. Hips and Advanced Wound Management, supports the investment case, but not enough to warrant a more positive stance.
At the same time, weaker U.S. Knee results, ongoing reimbursement headwinds in Advanced Wound Bioactives, and an ambitious medium-term growth plan introduce meaningful uncertainty. Management’s reaffirmed guidance, heavier second-half weighting, and the complexity around the LANDMARK knee launch and leadership transition make the path to its targets less certain, leading Roberts to reiterate a Hold rating and a reduced $32 price target rather than recommend adding exposure now.
Roberts covers the Healthcare sector, focusing on stocks such as AxoGen, Vericel, and Orthofix Medical. According to TipRanks, Roberts has an average return of 3.2% and a 44.44% success rate on recommended stocks.